Skip to main
BAX
BAX logo

Baxter (BAX) Stock Forecast & Price Target

Baxter (BAX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 67%
Sell 11%
Strong Sell 0%

Bulls say

Baxter International has demonstrated a positive sales trajectory within its Healthcare Systems & Technologies segment, with year-over-year sales increasing approximately 6% in 1Q25 and 2% in 2Q25, indicating robust demand for its medical products. The successful acquisition of Hillrom expanded Baxter's hospital-centric portfolio, providing a diversified range of essential medical equipment that supports revenue growth, while ongoing pricing initiatives are expected to contribute an estimated 100 basis points to sales growth in 2024 and 2025. As the market adjusts to new product launches and pricing strategies, Baxter is well-positioned to leverage its enhanced product offerings, suggesting a favorable outlook for sustained performance in the future.

Bears say

Baxter International's financial performance in 2Q25 exhibited significant shortfalls, as sales, margins, and earnings per share (EPS) failed to meet consensus expectations. Over the challenging period from 2021 to 2023, the company faced various operational missteps that resulted in inconsistent quarterly results and multiple negative guidance revisions. Compounding these issues, the company reported gross margins at 40.7% and operating margins at 15.1%, both of which fell notably below consensus estimates due to sales softness and manufacturing inefficiencies.

Baxter (BAX) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Baxter (BAX) Forecast

Analysts have given Baxter (BAX) a Hold based on their latest research and market trends.

According to 9 analysts, Baxter (BAX) has a Hold consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $25.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $25.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Baxter (BAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.